SHERIDAN, WY, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and does not constitute medical advice. Peptide therapies and NAD+-focused therapies require evaluation by licensed healthcare providers. Individual results vary, and not all individuals qualify for treatment. Consult a qualified healthcare professional before beginning any prescription therapy. This article contains affiliate links. If you access services through these links, a commission may be earned at no additional cost to you.
Search Term Context: "Best peptides for anti-aging" is used in this report to reflect common consumer search behavior and category language. This analysis does not rank therapies, endorse providers, or evaluate medical outcomes. It summarizes publicly available research and company disclosures to explain how consumers compare delivery methods and telehealth access considerations in 2026.
Consumer interest in peptide therapy options and NAD+-focused therapies has grown as published research examines NAD+ (nicotinamide adenine dinucleotide) and its roles in cellular processes. As more individuals evaluate their options, understanding the distinctions between delivery methods — injectable, oral, and intravenous — has become increasingly relevant for informed decision-making.
View the current RenuviaRX program offer (official RenuviaRX page).
Related reading: Consumer analysis of peptide therapy options for skin care applications
This consumer analysis examines the current landscape of delivery systems, publicly available research on NAD+ biology, and how telehealth platforms are expanding accessibility to prescription therapies that require clinical oversight.
Published Research Examining NAD+ and Cellular Pathways
Published research has examined NAD+ as a coenzyme involved in hundreds of metabolic processes, including cellular energy production, DNA repair pathways, and sirtuin activity. A 2020 paper in Nature Reviews Molecular Cell Biology documented that NAD+ levels decline with age, with researchers noting this decline correlates with changes in mitochondrial function and metabolic regulation.
It is important to note that published research on NAD+ biology and age-associated cellular changes reflects ongoing scientific investigation — these findings do not establish clinical outcomes for prescription therapies or predict results for any individual.
Research published in Science by Zhang et al. (2016) found that NAD+ repletion in aged mice was associated with changes in mitochondrial function and stem cell activity markers. However, animal studies do not directly translate to human outcomes, and these findings represent areas of ongoing investigation rather than established therapeutic protocols.
A 2024 study involving older adults with cognitive changes, referenced by research aggregators, examined NAD+ precursor supplementation and biomarker measurements. While noteworthy, these findings represent ongoing investigation rather than conclusive therapeutic claims, and individual responses cannot be predicted from population-level data.
View the current RenuviaRX program offer (official RenuviaRX page)
2024-2025 Research Developments: What Recent Publications Reveal
The scientific landscape around NAD+ continues to evolve, with recent publications offering additional data on cellular mechanisms and supplementation approaches.
Cellular Entry Research
A September 2024 study examined whether NAD+ can enter cells through connexin 43 hemichannels, challenging previous assumptions about NAD+ cellular uptake mechanisms. Published by iX Biopharma researchers, this finding contributes to ongoing investigation of how delivery method characteristics may influence outcomes.
Systems-Based Approaches
Research published in npj Aging (Henderson et al., 2024) examined a multi-targeted approach to NAD+ pathways, measuring whole blood NAD+ concentrations and related biomarkers among participants. These findings add to the growing body of research, though they do not establish clinical protocols.
Mitochondrial Research
University of Bergen researchers published December 2024 findings examining how mitochondria function as NAD+ reservoirs. This mechanistic research deepens understanding of NAD+ biology without establishing specific therapeutic claims.
These developments represent active scientific inquiry rather than established therapeutic protocols. Research translation takes time, and findings from controlled studies do not predict individual responses to any specific therapy.
Delivery Method Characteristics: How Consumers Compare Options
Consumers comparing NAD+-related therapies often focus on delivery-method differences such as administration setting, supervision requirements, and bioavailability characteristics. These factors do not imply that any method works better for all individuals, and consumers should discuss their specific situation with a licensed clinician.
Oral Supplementation
Oral NAD+ precursors such as NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) must pass through gastrointestinal processes before absorption. Research published in Nature Communications by Martens et al. (2018) examined oral NR supplementation and NAD+ level measurements in middle-aged and older adults, with variability observed among participants.
The convenience of oral supplementation makes it an accessible option for many consumers. That said, absorption characteristics represent one factor worth discussing with healthcare providers.
Intravenous Administration
IV NAD+ therapy delivers the compound directly into the bloodstream, bypassing digestive processes entirely. Clinical settings offering IV NAD+ infusions describe direct delivery characteristics, though this method typically requires in-person appointments at specialized facilities.
Cost is a significant consideration with IV delivery. Industry estimates suggest IV NAD+ sessions at clinical facilities may involve substantial per-session costs, varying by location, dosage, and facility.
Subcutaneous Injection
Injectable NAD+ administered subcutaneously represents a middle-ground approach — offering different bioavailability characteristics compared to oral supplementation while enabling home-based administration under clinical supervision.
Telehealth platforms have emerged as access points for prescription injectable therapies, providing clinical oversight while addressing the logistical challenges associated with frequent in-person clinic visits.
Consumers can review current availability and state coverage details via View the current RenuviaRX program offer (official RenuviaRX page).
Telehealth Platforms and Prescription Therapy Access
The expansion of telehealth services has created new pathways for consumers seeking prescription therapies that require clinical oversight. These platforms typically operate through a three-entity structure designed to maintain appropriate separation of functions.
Understanding the Three-Entity Model
Telehealth platforms that facilitate prescription therapy access generally involve three distinct entities:
The Technology Platform — This entity provides the digital infrastructure connecting consumers with healthcare services, manages administrative functions, and coordinates care delivery. Importantly, the platform itself is not a healthcare provider.
Licensed Healthcare Providers — These are independent, board-certified physicians who evaluate patient information and determine treatment appropriateness. Clinical decisions, including whether a prescription is issued, are made solely by these independent licensed providers. Prescription issuance is never guaranteed.
Compounding Pharmacies — These licensed facilities prepare and dispense prescription medications according to provider specifications and regulatory requirements.
This structure ensures that clinical decision-making remains with licensed providers while technology platforms handle coordination and accessibility functions.
RenuviaRX: Platform Structure and Access Information
One platform operating in this space is RenuviaRX, which facilitates access to NAD+ injections and related therapies through its telehealth infrastructure.
According to the company's published materials, RenuviaRX functions as a technology platform — it is not itself a healthcare provider. The company's terms of service state that telehealth services are provided through its clinical partner, Beluga Health, P.A., with prescriptions fulfilled by licensed pharmacy partner Strive Pharmacy (Gilbert, AZ; Pharmacy License #99-9817).
How the Platform Describes Its Process
The company states that its process begins with an online health assessment, which is then reviewed by board-certified physicians within the Beluga Health network. If a licensed provider determines that therapy is appropriate based on an individual's health factors, a prescription may be issued and fulfilled through Strive Pharmacy.
It bears repeating: clinical decisions, including whether a prescription is issued, are made solely by independent licensed providers and are never guaranteed.
The company notes that medications ship directly to patients along with subcutaneous injection supplies and instructional materials. According to the platform's FAQs, patients complete self-administration after reviewing the provided guidance.
Pricing and Availability Information
According to the company, RenuviaRX lists NAD+ injection programs starting at approximately $179 per month. The company states this may include clinician review, prescription fulfillment if approved, and shipping. As with any service, pricing and program terms may change and should be confirmed directly on the official website before making any decisions.
Additional therapies listed on the platform include Vitamin B12 + MIC (starting at approximately $99), Glutathione (starting at approximately $109), and L-Carnitine (starting at approximately $99), according to company materials.
The platform indicates services are currently available in 47 states. Per company disclosures, telehealth services are not available in Alaska, Mississippi, or New Jersey due to state regulatory requirements.
Consumers can review current availability and state coverage details via View the current RenuviaRX program offer (official RenuviaRX page).
Understanding Therapy Categories: NAD+ in Context
Consumers researching peptides and NAD+ programs encounter various compound categories, each with distinct characteristics and regulatory classifications. For those specifically interested in skin-focused peptide applications, this related consumer analysis examines injectable options and delivery considerations. Here is a brief overview:
Cellular Metabolism Compounds
NAD+ and its precursors (NMN, NR) relate to cellular energy pathways and repair mechanisms. Worth noting: NAD+ is technically a dinucleotide rather than a traditional peptide structure, though consumers often encounter it alongside peptide therapy discussions due to overlapping areas of interest.
Antioxidant Support Compounds
Glutathione is described in published literature as involved in cellular protection against oxidative stress. Research indicates that glutathione levels show age-associated changes in population studies.
Metabolic Support Compounds
L-Carnitine facilitates fatty acid transport into mitochondria. Published research has examined L-Carnitine supplementation across various study populations, with results varying by individual.
B-Vitamin Therapy
Vitamin B12, particularly in injectable form, supports neurological function pathways. Research indicates that injectable B12 achieves different serum levels than oral supplementation — a consideration particularly relevant for individuals with absorption challenges.
RenuviaRX lists access to multiple compound categories — NAD+, Glutathione, L-Carnitine, and Vitamin B12 + MIC — through its telehealth platform. Licensed providers determine appropriateness based on each individual's health profile.
Who May Consider Telehealth Therapy Access: A Self-Assessment Framework
Rather than relying on testimonials, consumers can evaluate whether telehealth therapy access warrants further investigation based on their own circumstances. Here are some factors to consider:
Characteristics That May Align With Telehealth Interest
Individuals interested in exploring prescription therapy options may find telehealth platforms logistically compatible if they are comfortable with remote clinical evaluation processes and prefer the convenience of home-based care.
Those who live in states where telehealth services operate — and who are comfortable with self-administration protocols under clinical guidance — may find this access pathway worth exploring.
Situations Where Other Approaches May Be Preferable
Individuals with complex medical histories, multiple medications, or specific health conditions should prioritize in-person clinical evaluation before considering telehealth options. There is no substitute for hands-on care when circumstances warrant it.
Those located in states where specific telehealth services are unavailable will need to explore alternative access pathways.
Consumers primarily interested in general wellness support may find oral supplements or lifestyle modifications to be more appropriate starting points than prescription therapies requiring clinical oversight.
Questions to Consider Before Proceeding
- Have I discussed my interest with my primary care provider?
- Am I located in a state where the telehealth service operates?
- Do I have health conditions that require hands-on clinical evaluation?
- Am I comfortable with self-injection protocols following clinical instruction?
- Have I reviewed the platform's terms, pricing, and refund policies?
Honest answers to these questions can help determine appropriate next steps rather than assuming universal suitability.
Consumers can review current availability and state coverage details via View the current RenuviaRX program offer (official RenuviaRX page).
Regulatory Context and Platform Considerations
Consumers evaluating telehealth platforms should understand the regulatory framework governing these services.
Compounding Pharmacy Regulations
Prescription NAD+ is typically prepared by compounding pharmacies operating under state and federal regulations. According to FDA guidance, compounded medications are not FDA-approved as finished products. Instead, they are prepared using active ingredients under clinical direction and pharmacy licensing requirements.
Strive Pharmacy, identified as RenuviaRX's pharmacy partner, operates under Arizona pharmacy regulations with License #99-9817 according to company disclosures.
Telehealth Prescription Authority
Telehealth prescribing authority varies by state, which explains geographic service limitations. Regulatory frameworks govern aspects of telehealth prescribing, and service availability reflects compliance with applicable requirements.
Insurance and Payment Considerations
According to general industry patterns, most telehealth prescription therapy services operate on a direct-pay basis. Coverage through health insurance plans is typically unavailable for these services, though HSA/FSA eligibility may apply depending on individual plan rules. Consumers should verify payment options with their plan administrators.
What Published Research Does Not Establish
Balanced consumer analysis requires acknowledging research limitations alongside reported findings.
Clinical studies on NAD+ supplementation in humans remain relatively limited in scale and duration compared to pharmaceutical development standards. Most mechanistic understanding derives from preclinical research with varying translational relevance.
Long-term data on injectable NAD+ in healthy adults has not been established through large-scale clinical trials. While NAD+ is naturally present in the body and generally described as well-tolerated in published literature, individual responses may vary.
Specific outcome claims — particularly regarding disease prevention, treatment, or reversal — exceed what current evidence establishes. Consumers should maintain realistic expectations and view prescription therapies as one consideration within comprehensive health approaches discussed with qualified providers.
Published research has examined NAD+ biology and age-associated changes in cellular pathways; however, these findings reflect ongoing scientific investigation and do not establish clinical outcomes for prescription therapies or any individual.
Contact and Verification Information
Consumers interested in learning more about RenuviaRX services can verify company information through the following published sources:
According to company disclosures, customer support is available at support@renuviarx.com. The company also lists a phone contact at +1 (206) 814-5447.
The clinical partner, Beluga Health, P.A., maintains information at https://www.belugahealth.com, according to company terms.
Strive Pharmacy's contact information includes: 1275 E Baseline Rd, Gilbert, AZ 85233; Phone: 480-626-4366; Email: Info@strivepharmacy.com.
Consumers can review current availability and state coverage details via View the current RenuviaRX program offer (official RenuviaRX page).
Summary: Navigating Therapy Options in 2026
Consumer interest in peptide therapy options and NAD+-focused therapies reflects broader trends toward exploring approaches to cellular health pathways. Published research has examined NAD+ as a molecule of biological significance, while ongoing investigation continues examining supplementation approaches.
For consumers evaluating options, key considerations include:
- Delivery method characteristics and administration settings
- Clinical oversight and prescription requirements
- Platform verification and regulatory compliance
- Individual health circumstances and provider consultation
- Realistic expectations aligned with current published research
Telehealth platforms have expanded access to prescription therapies while maintaining clinical oversight through three-entity structures. Consumers benefit from understanding how these models operate and verifying platform credentials before engagement.
Clinical decisions, including whether a prescription is issued, are made solely by independent licensed providers and are not guaranteed.
As with any health decision, consultation with qualified healthcare providers remains essential. Published research provides context for interest, but individual treatment decisions should reflect personal health profiles and professional medical guidance.
Disclaimers
Content and Medical Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. The research findings described here do not constitute outcome guarantees. NAD+ therapy requires evaluation by a licensed clinician who will determine whether treatment is appropriate based on your individual health factors. The information provided does not replace the professional judgment of your healthcare provider.
Professional Medical Disclaimer: This article is educational and does not constitute medical advice. If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting any prescription treatment. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician's guidance and approval.
Compounding Notice: NAD+ injectable therapy as described is prepared as a compounded prescription medication by licensed pharmacies based on individual prescriptions. Compounded medications are not reviewed or approved by the FDA as finished products. They are prepared using active ingredients sourced from FDA-registered facilities under the direction of prescribing clinicians.
Results May Vary: Individual results vary based on factors including age, baseline health condition, lifestyle factors, consistency of use, genetic factors, current medications, and other individual variables. Published research findings do not predict individual outcomes, and results are not guaranteed for anyone.
FTC Affiliate Disclosure: This article contains affiliate links. If you access services through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All descriptions are based on published research and publicly available company information.
Pricing Disclaimer: All prices and program terms mentioned were based on publicly available information at the time of publication (January 2026) but are subject to change without notice. Always verify current pricing and terms on the official website before making any decisions.
Telehealth Disclosure: Telehealth services referenced are provided through licensed clinical partners. The technology platform facilitating access is not itself a healthcare provider. Clinical decisions regarding treatment appropriateness rest with independent licensed physicians. Prescription issuance is not guaranteed and depends entirely on individual clinical evaluation.
Publisher Responsibility Disclaimer: The publisher of this article has made every effort to ensure accuracy at the time of publication. We do not accept responsibility for errors, omissions, or outcomes resulting from the use of this information. Readers are encouraged to verify all details directly with referenced platforms and their healthcare providers before making decisions.
Regulatory Context: The telehealth and compounding pharmacy industries operate under evolving regulatory oversight. Consumers should review the most current information about any service's compliance and regulatory standing before proceeding.
Referenced Publications:
- Covarrubias, A.J., et al. "NAD+ metabolism and its roles in cellular processes during ageing." Nature Reviews Molecular Cell Biology, vol. 22, 2020. https://doi.org/10.1038/s41580-020-00313-x
- Zhang, H., et al. "NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice." Science, 2016. https://doi.org/10.1126/science.aaf2693
- Martens, C.R., et al. "Chronic Nicotinamide Riboside Supplementation Is Well-Tolerated and Elevates NAD+ in Healthy Middle-Aged and Older Adults." Nature Communications, vol. 9, 2018. https://doi.org/10.1038/s41467-018-03421-7
- Bonkowski, M.S., and Sinclair, D.A. "Slowing Ageing by Design: The Rise of NAD+ and Sirtuin-Activating Compounds." Nature Reviews Molecular Cell Biology, vol. 17, 2016. https://doi.org/10.1038/nrm.2016.93
- Abdellatif, M., et al. "NAD+ Metabolism in Cardiac Health, Aging, and Disease." Circulation, 2021. https://doi.org/10.1161/CIRCULATIONAHA.121.056589
- Henderson, J.D., et al. "The use of a systems approach to increase NAD+ in human participants." npj Aging, vol. 10, 2024. https://doi.org/10.1038/s41514-023-00134-0
- iX Biopharma. "New Study Demonstrates that SL-NAD+ delivers NAD+ into Cells." BioSpace, September 2024. https://www.biospace.com/press-releases/new-study-demonstrates-that-sl-nad-delivers-nad-into-cells
About This Analysis: This consumer analysis was prepared for informational purposes to help readers understand therapy options, delivery method characteristics, and platform access pathways. The information reflects publicly available research and company disclosures as of January 2026. It is not intended as medical advice or an endorsement of any particular therapy or provider.
Contact: For additional information regarding RenuviaRX services, contact support@renuviarx.com or visit the official website.
support@renuviarx.com
